|
Phase Ib study of a novel bivalent IAP antagonist APG-1387 in combination of pembrolizumab for patients with advanced solid tumors. |
|
|
Research Funding - Abbvie (Inst); Apexian Pharmaceuticals (Inst); Asana Biosciences (Inst); Ascentage Pharma (Inst); Astex Pharmaceuticals (Inst); Celgene (Inst); Compugen (Inst); Constellation Pharmaceuticals (Inst); Coordination Therapeutics (Inst); Eisai (Inst); Five Prime Therapeutics (Inst); GlaxoSmithKline (Inst); Gossamer Bio (Inst); Incyte (Inst); Macrogenics (Inst); Merck (Inst); Seven and Eight Biopharmaceuticals (Inst); Syndax (Inst) |
Travel, Accommodations, Expenses - Asana Biosciences |
|
|
Consulting or Advisory Role - Innovent Biologics |
Research Funding - Alexion Pharmaceuticals (Inst); Alexo Therapeutics (Inst); Apexian Pharmaceuticals (Inst); Asana Biosciences (Inst); Ascentage Pharma (Inst); BeiGene (Inst); Cerulean Pharma (Inst); Constellation Pharmaceuticals (Inst); Coordination Therapeutics (Inst); CytomX Therapeutics (Inst); Formation Biologics (Inst); Forty Seven (Inst); Incyte (Inst); InhibRx (Inst); Innovent Biologics (Inst); Jounce Therapeutics (Inst); Livzon (Inst); Loxo (Inst); Macrogenics (Inst); Merck (Inst); Northern Biologics (Inst); Pfizer (Inst); Regeneron (Inst); Symphogen (Inst); TaiRx, Inc. (Inst); Tesaro (Inst) |
|
|
Employment - Ascentage Pharma |
|
|
Employment - Ascentage Pharma |
|
|
No Relationships to Disclose |
|
|
Employment - Ascentage Pharma |
|
|
Employment - Ascentage Pharma |
|
|
No Relationships to Disclose |
|
|
Employment - Ascentage Pharma; Ascentage Pharma; Ascentage Pharma |
Leadership - Ascentage Pharma; Ascentage Pharma; Ascentage Pharma |
Stock and Other Ownership Interests - Ascentage Pharma |
|
|
Employment - Ascentage Pharma; Ascentage Pharma; HealthQuest Pharma |
Leadership - Ascentage Pharma; Ascentage Pharma; HealthQuest Pharma |
Stock and Other Ownership Interests - Ascentage Pharma |